{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-049874","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.858640+00:00","generated_at":"2026-05-15T03:32:01.431442+00:00","sec_items":["7.01","9.01","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gilead completes $7.8B acquisition of Arcellx; adds anito-cel CAR T therapy for multiple myeloma","bullets":["Purchase price $115/share cash plus $5 CVR (contingent on $6B anito-cel sales by end-2029); total implied equity ~$7.8B.","Tender offer accepted 38.8M shares (~77.2% of outstanding); merger completed April 28, 2026.","Expected EPS dilution of ~$5.57-$5.67 in 2026; ex-R&D, modestly dilutive 2026-27, accretive from 2028.","Full control of anito-cel eliminates profit-sharing/royalty obligations; accelerates development and commercial launch.","Arcellx becomes wholly owned subsidiary of Gilead; ACLX common stock to be delisted from Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-049874","json":"https://secwatch.observer/filing/0001104659-26-049874.json","markdown":"https://secwatch.observer/filing/0001104659-26-049874.md","text":"https://secwatch.observer/filing/0001104659-26-049874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000110465926049874/0001104659-26-049874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000110465926049874/tm2612748d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:32:01.431442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}